L2 MS Flashcards

1
Q

what is multiple sclerosis

A
  • An autoimmune disorder which causes attacks of demyelination, leading to permanent damage of the myelin sheath.
  • The myelin sheath is a protective coating of the axons in the nerve fibres of the CNS.
  • Attacks on the myelin sheath lead to an inability of the nerve fibres to communicate.
  • The body can repair myelin, but not perfectly, and the damage leads to lesions or scars (which gives the disorder its name).
  • Over time, degredation of the myelin can become permanent, leading to an increase in disability
  • As the disease progresses it attacks the cell bodies, and leads to cortical atrophy (the shrinking of the cerebral cortex).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

where does MS get its name

A

multiple sclerosis means many scars, referring to the many lesions or scars caused by demylination attacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how many people in ireland live with MS

A

around 9000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the age of onset of MS

A

20-40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is the mean age of onset for MS

A

28

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

influencing factors in the development of MS

A
  • geographical location - more northern areas are more likely to develop MS (possible due to less vitamin D exposure)
  • race - white people are more likely to develop MS than other races
  • possible viral triggers - including herpes, severe flu and epstein-barr virus
  • family history
  • history of smoking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

prevalence of MS

A
  • 100 –140 per 100,000 in England and Wales
  • 170 per 100,000 un Northern Ireland.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

symptoms of MS

A
  • Fatigue, cognitive changes (seen as a slowing down of mental faculties).
  • Visual loss, sensory disturbance, limb weakness, balance and coordination issues.
  • Bladder problems, pain, speech, and swallowing difficulties.
  • Generally very specific to begin with → visual acuity or weakness in limbs symptoms; more lateral difficulties such as speech and swallowing tend to come later.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

characteristic features

A
  • Optic neuritis: Painful visual loss.
  • Internuclear ophthalmoplegia: Double vision.
  • Fatigue.
  • Lhermitte’s phenomenon: Sudden brief pain or electrical buzzing sensation.
  • Uhthoff’s phenomenon: Worsening symptoms with heat - due to less protection of the nerves.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

5 subtypes of MS

A
  • clinically isolated syndome
  • relapsing-remitting MS
  • secondary progressive MS
  • progressive relapsing MS
  • primary progressive MS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

clinically isolated syndrome

A

one or two episodes followed by stabilisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

relapsing-remitting MS

A

unpredicatable attacks which may or may not leave permanent deficits followed by periods of remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

secondary progressive MS

A

initial relapsing-remitting MS which suddenly begins to have decline without periods of remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

progressive-relapsing MS

A

steady decline since onset with super-imposed attacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

primary-progressive MS

A

steady increase in disability without attacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

diagnostic criteria for MS

A
  • McDonald Criteria
  • Objective evidence of ≥2 attacks disseminated in space and time.
  • Diagnostic tools include MRI and lumbar puncture - used to confirm or in cases of less objective clinical evidence.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

three types of investigations for MS

A
  • MRI
  • lumbar puncture
  • visual evoked potential
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

MRI - test for MS

A
  • damage appears as white, healthy tissue appears as black
  • over the course of years MRIs can reveal distributed plaques across the brain affecting movement and cognition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

lumbar puncture - test for MS

A
  • looks for oligoclonal bands in cerebro-spinal fluid
  • presense of these is indicative of MS
  • representative of the immune system attacks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

visual evoked potential - test for MS

A
  • Assesses the speed of passive information processing.
  • Electrodes are placed on the individual’s scalp.
  • They are presented with a flashing checkerboard.
  • Delayed signal due to optic path damage leading to sluggishness identifying changes in the visual field.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

prognosis of MS

A
  • the subtype of MS tends to predict its prognosis (as well as the degree of disability across the lifespan)
  • there is usually a shortened life expectance
  • 50% of sufferers cannot walk unaided after 16 years of symptoms
  • a younger age at onset correlates with a slower disease progression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what are the aims of treamtent for MS

A
  • Reduce relapse rate and disability progression.
  • Slower MRI lesion accumulation.
  • Most active treatments are aimed at RRMS.
  • Symptomatic treatments available for all types.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

three examples of disease-modifying treatments

A
  • injections
  • IV infusions
  • chemotherapeutic agent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

name two MS treatments that come in the form of injections

A
  • interferon beta
  • glatiramer acetate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

what is interferon beta

A

treament in the form of an injection which was once the most commonly used treatment for MS

26
Q

side effects of interferon beta

A

flu-like symptoms (usually fade with continued therapy), depression, elevation of liver enzymes

27
Q

what is glatiramer acetate

A

MS treatment which comes in the form on an injection; often used for RRMS, can reduce relapse rate by 1/3

28
Q

what is the brand name for natalizumab

29
Q

how does natalizumab (tysabri) work

A

prevents immune systems cells from entering the CNS

30
Q

why use natalizumab (tysabri)

A

it’s very effective and possibly leads to a larger reduction in relapse rate than other treatments

31
Q

one danger of using natalizumab (tysabri)

A

it’s associated with an increased risk of a very serious viral brain infection called progressive multifocal leukoencephalopathy (PML). Regular blood tests for antibodies to this virus can help address this risk

32
Q

what is mitoxantrone

A
  • a potent chemotherapeutic agent
  • used for agressive progressive MS
33
Q

what risks are associated with mitoxantrone

A

cardiotoxicity & leukemia

34
Q

treatment for relapses

A

high-dose steriods for recovery

35
Q

treatment for spasticity

A
  • baclofen
  • tizanidine
  • stretching and exercising affected muscles
36
Q

tremour treatment

A
  • assistive devices
  • medications
  • deep brain stimulation
37
Q

ataxia treatments

A
  • assistive walking devices
  • physiotherapy
  • occupational therapy
38
Q

bladder issue treatments

A
  • medications
  • hydration changes
  • self-cathterisation
39
Q

fatigue treatments

A
  • physiotherapy
  • occupational therapy
40
Q

pain treatments

A

medications and alternative therapies

41
Q

eye/vision difficulty treatments

A
  • vision therapy exercises
  • special eyeglasses
  • resting the eyes
42
Q

depression treatments

43
Q

what does SSRI stand for

A

selective serotonin reuptake inhibitor

44
Q

why use SSRIs over other anti-depressant medication

A

less likely to cause fatigue

45
Q

members of the MS MDT

A
  • neurologist
  • neurorehabilitation specialist
  • MS specialist nurses
  • physiotherapist
  • speech and language therapist
  • occupational therapist
  • social services
  • palliative care
46
Q

impact of MS

A
  • affects young people’s work, family and finances
  • significant psychological and cognitive effects such as depression, anxiety and potential dementia
  • cognitive impairment affects up to 75% of individuals with MS
47
Q

what is cognitive impairment

A

decline in ability to think, learn and remember

48
Q

what role does an SLT have in MS management

A

assessment and intervention in the areas of:
- Speech: Spastic-ataxic dysarthria.
- Language: Anomia, aphasia.
- Swallowing

49
Q

what is the prevalence of dysarthria in people with MS

50
Q

in which type of MS is the dysarthria typically mild

51
Q

in which types of MS is the dysarthria typically moderate to severe

A
  • Sp-MS
  • PP-MS
52
Q

symptoms of dysarthria in MS

A
  • Articulation: Slow rate, imprecise consonants
  • Phonation: Pitch and loudness instability
  • Respiration: Reduced phonatory time, expiratory pressure
  • Prosody: Variable intonation, pitch, and volume
53
Q

impact of dysarthria on quality of life in MS

A

Negatively affects employment status, social participation, and overall quality of life

54
Q

key interventions for dysarthria in MS

A
  • Respiration techniques.
  • Energy conservation and loudness regulation.
  • Prosody.
  • Paced speech with visual feedback.
  • Adaptive compensation strategies.
  • Education.
  • AAC support, accounting for hand function and vision.
  • Lee Silverman Voice Treatment (LSVT).
55
Q

prevalence of dysphagia in MS

56
Q

how does the relapse/remission cycles present in MS affect swallowing issues

A

means the difficulties may wax and wane

57
Q

examples of contributing factors to swallowing difficulties in MS

A
  • fatigue
  • heat sensitivity
  • physical disability (hand tremors)
58
Q

two assessment tools

A
  • Multiple Scelerosis Swallowing Performance Scale
  • DYMUS
59
Q

what is the Multiple Scelerosis Swallowing Performance Scale

A

7 point scale rating swallow from normal to NPO

60
Q

what is DYMUS

A

10 question questionnaire for the assessment of dysphagia in MS.

61
Q

key strategies for the management of dysphagia in MS

A
  • Remove distractions during meals
  • Sensory stimulation and proper posture
  • Maintain hydration, avoid warm environments
  • “Little and often” approach
  • Compensatory techniques (e.g., head postures)
  • Rehabilitation strategies (e.g., Expiratory Muscle Strength Training - EMST)
  • Diet modifications and alternative feeding options